News
SNY
53.10
+3.71%
1.90
FLUZONE® HIGH-DOSE QUADRIVALENT VACCINE REMAINS PREFERENTIALLY RECOMMENDED TO PROTECT ADULTS 65 YEARS OF AGE AND OLDER AGAINST INFLUENZA
Reuters · 10h ago
Dodge & Cox Stock Fund Q2 2024 Shareholder Letter
Seeking Alpha · 10h ago
Pharma Stock Roundup: AZN, SNY, ABBV Q2 Earnings, PFE & MRK's Positive Pipeline News
NASDAQ · 11h ago
DZ BANK AG Remains a Hold on Sanofi (SNYNF)
TipRanks · 11h ago
Sanofi ending development of mid-stage dwarfism therapy
Sanofi ending development of mid-stage dwarfism therapy. French pharma will also end development of riliprubart in rare autoimmune disorder cold agglutinin disease. Sanofi is currently in phase 2 to treat achondroplasia, the genetic disorder that causes dwarfism.
Seeking Alpha · 1d ago
Sanofi (SNY) Q2 2024 Earnings Call Transcript
Sanofi (SNY 3.69%) Q2 2024 Earnings Call for the period ending June 30, 2024. Dupixent sales exceeded the 3 billion euros mark in a single quarter. Paul Hudson, Sanofi's chief executive officer, will discuss the company's results.
The Motley Fool · 1d ago
ONTARIO MINISTRY OF HEALTH ANNOUNCES A UNIVERSAL PUBLIC PROGRAM WITH BEYFORTUS® THIS RSV SEASON
Reuters · 1d ago
Stocks Rebound As US Economy Flexes Muscles, Small Caps Rally, Gold Falls: What's Driving Markets Thursday?
All eleven sectors of the S&P 500 posted gains on Thursday. The U.S. Economy posted 2.8% real growth in the second quarter. The Dow Jones Industrial Average rose 1.3% and the Nasdaq 100 was up 0.9%. Treasury yields fell significantly, and gold fell 1.6%.
Benzinga · 1d ago
Sanofi Q2 Results Show Strong Growth, Upbeat 2024 Outlook
TipRanks · 1d ago
Sanofi Reports Increased Total Assets
TipRanks · 1d ago
Sanofi (SNY) Q2 Earnings Beat, Sales Miss, 2024 View Raised
NASDAQ · 1d ago
Sector Update: Health Care Stocks Mixed Premarket Thursday
NASDAQ · 1d ago
AstraZeneca (AZN) Beats on Q2 Earnings & Sales, Ups '24 View
NASDAQ · 1d ago
Sanofi Raises 2024 Profit Outlook On Strong Q2 Earnings, Blockbuster Drug Dupixent Sees Strong Demand
Sanofi SA reported a second-quarter business operating income of 2.8 billion euros. The company reported second- quarterly sales of $11.57 billion. Sales increased 7.8% year-over-year and 10.2% on constant currency in the quarter.
Benzinga · 1d ago
25 Best Artificial Intelligence Stocks to Buy Right Now
Artificial intelligence is revolutionizing industries across the board. These 25 companies span the spectrum, providing investors with a diversified basket of AI-centric equities. Companies like Alphabet, Microsoft, and Nvidia are leading the charge in AI development. The best way to gain exposure to the AI market is to buy a basket of these 25 companies.
The Motley Fool · 1d ago
AstraZeneca slips despite 2024 guidance raise on medicines demand
AstraZeneca slips despite 2024 guidance raise on medicines demand. Anglo-Swedish drugmaker beat analysts' expectations with its Q2 2024 financials. AstraZeneca's ADRs fell 4% premarket Thursday. The company raised its full-year growth outlook due to strong demand for its medicines.
Seeking Alpha · 1d ago
Nasdaq, S&P Futures Slide On More Negative Tech Tidings As Focus Shifts To Q2 GDP Data: Strategist Says Trump Trades May Not Work Even If Ex-President Retakes White House
Major index futures look to open lower on Thursday. The tech space could drag the broader market lower after a few disappointing earnings reports. The major indices closed lower on Wednesday. Investors are looking ahead to second-quarter GDP data and more earnings. Mega-cap earnings proved to be the undoing of the market on Wednesday, with the S&P 500 and the Nasdaq Composite posting their worst closes since 2000.
Benzinga · 1d ago
Sanofi: Strong Q2 Performance and Promising Outlook Justify Buy Rating
TipRanks · 1d ago
UPDATE 2-European shares fall as earnings deluge disappoints
European shares fall as earnings deluge disappoints STOXX 600 down 0.7% Universal Music Group slumps as streaming growth disappoints Kering down after weak H2 forecast. The pan-European SToXX 600 index closes 0.8% lower. Media shares decline 3% after Universal Music reports lower-than-expected second quarter revenue. Tech and luxury shares also fall as investors flee to safe haven assets.
Reuters · 1d ago
LIVE MARKETS-STOXX 600 drops to 12-week low as earnings fail to impress
STOXX 600 down 1.2% to 12-week low as earnings fail to impress. France's CAC 40 hits lowest level since January. Universal Music Group tumbles 30% after disappointing results. UMG on track for biggest daily drop on record. Healthcare is one of the only bright spots.
Reuters · 1d ago
More
Webull provides a variety of real-time SNY stock news. You can receive the latest news about Sanofi FR through multiple platforms. This information may help you make smarter investment decisions.
About SNY
Sanofi SA is a France-based healthcare company based in France. The Company focuses on patient needs and engages in the research, development, manufacture, and marketing of therapeutic solutions. Its three operating segments are: Pharmaceuticals, Consumer Healthcare (CHC), and Vaccines. The Pharmaceuticals includes: Immunology, Multiple Sclerosis / Neurology, Oncology, Rare Diseases, Rare Blood Disorders, Cardiovascular, Diabetes, Established Prescription Products. The Vaccines segment comprises, for all geographical territories, the commercial operations of Sanofi Pasteur, together with research, development, and production activities dedicated to vaccines. The CHC segment comprises the commercial operations for Sanofi’s Consumer Healthcare products, together with research, development and production activities dedicated to those products. The Company’s products developed in collaboration or franchise include Dupixent, Aubagio, Lemtrada, Cerezyme, Lumizyme, Jevtana, Fabrazyme.